Table 4.
In vitro cytotoxic activity of T. alternans EOa.
| IC50 (μg/ml) ± S.D.b | |||
|---|---|---|---|
| Compound | A375c | MDA-MB 231d | HCT116e |
| Essential oil | 5.51 ± 0.34 | 5.9 6 ± 0.46 | 8.45 ± 0.61 |
| (E)-Nerolidol | 2.92 ± 0.09 | 5.76 ± 0.29 | 4.13 ± 0.18 |
| (13.13 ± 0.43) | (25.90 ± 1.31) | (18.57 ± 0.81) | |
| Neryl acetate | 28.05 ± 1.27 | 27.37 ± 1.87 | 45.61 ± 2.83 |
| (142.9 ± 6.47) | (139.5 ± 9.53) | (232.4 ± 14.4) | |
| Nerol | 75.83 ± 3.97 | 24.44 ± 1.66 | 33.49 ± 4.53 |
| (491.6 ± 25.7) | (158.4 ± 10.8) | (217.1 ± 29.4) | |
| Positive control | |||
| Cisplatin | 0.43 ± 0.045 | 2.94 ± 0.23 | 2.42 ± 0.21 |
| (1.43 ± 0.15) | (9.80 ± 0.76) | (8.06 ± 0.70) | |
a
Sample was obtained from population growing in Nová Sedlica.
b
IC50= The concentration of compound that affords a 50% reduction in cell growth (after 72 h of incubation).
c
Human malignant melanoma cell line.
d
Human breast adenocarcinoma cell line.
e
Human colon carcinoma cell line. Bracketed IC50 values are expressed in μM ± S.D.